Pharmacogenomics of Type I interferon therapy: A survey of response-modifying genes

Catherine King, Pablo Villoslada, Koen Vandenbroeck

Research output: Contribution to journalShort surveypeer-review

25 Citations (Scopus)


Interferon-β (IFN-β) is routinely prescribed as an immunomodulatory treatment for multiple sclerosis (MS), but is associated with variable clinical efficacy. Ideally an early predictor of response status would allow more rational provision of this therapy. Both pharmacogenomic and expression analysis have highlighted IFN-β regulated genes which may influence treatment efficacy. In this review we have summarized and discussed the main genes identified by these studies in MS patients, and supplemented this with data from similar studies of Type I IFN treatment in hepatitis.

Original languageEnglish
Pages (from-to)211-222
Number of pages12
JournalCytokine and Growth Factor Reviews
Issue number3-4
Publication statusPublished or Issued - 1 Jun 2007
Externally publishedYes


  • Gene expression
  • Hepatitis
  • Interferon
  • Multiple sclerosis
  • Pharmacogenomics
  • Polymorphism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this